US Patent

US9474779 — Therapeutically active compositions and their methods of use

Method of Use · Assigned to Agios Pharmaceuticals Inc · Expires 2033-08-19 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of treating cancer caused by mutant IDH1/2 alleles by administering a compound described in the patent.

USPTO Abstract

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Drugs covered by this patent

Tibsovo (IVOSIDENIB) · Servier

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2534`	—	Tibsovo

Patent Metadata

Patent number: US9474779
Jurisdiction: US
Classification: Method of Use
Expires: 2033-08-19
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Agios Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.